Duchenne muscular dystrophy, or DMD, is a severe genetic disorder, typically affecting males, and is characterized by progressive ...

KB Home (NYSE: KBH) fell 6% after quarterly EPS missed estimates, due in part to lower margin. The home builder also trimmed its full year margin forecas ...

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...

Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to ...

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531.

The stock is trading at $8.18, up $2.84, gaining 53.18% on volume of over 12.4 Million shares. The stock had a days' high of $8.33.

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular ...

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, has appointed a new chief artificial ...

We recently watched a Netflix movie called “White Tiger” that aligned with a book we were rereading called “Untamed” by Glennon Doyle. Reading books a second and third time rocks ...

Wave Life Sciences said new Phase 2 biomarker data for its exon-skipping therapy are promising for certain patients with ...

* WAVE LIFE SCIENCES LTD - COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $175 MILLION IN AGGREGATE OF ITS ORDINARY SHARES Source text for Eikon: Further company coverage: ...

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers ...